• Dr. Yotam Levin - CEO
    Dr. Yotam Levin - CEO

    Dr. Yotam Levin has been the CEO of NanoPass Technologies Ltd. since 2002.  He is in charge of the Company's strategy, business development, and all clinical activities. Under his supervision the company successfully licensed its product with the FDA and the European authorities, and conducted pioneering intradermal vaccination studies. Prior to becoming CEO at NanoPass, Dr Levin was head of the biomedical consulting practice at Global Business Solutions, an Israeli strategic consulting firm. Dr Levin holds an MD degree and an MBA (finance), both from Tel Aviv University, Israel. Dr Levin authored several key publications in leading journals such as the Lancet Infectious Diseases, Vaccine, Journal of Infectious diseases (JID) and Human Vaccines & Immunotherapeutics (HV&I(, and participated in authoring over a two-dozen patent applications. He serves as a frequent reviewer for Vaccine, JID and HV&I, and was a Guest Editor for Vaccine’s Skin Vaccination Summit 2015. In his spare time, he runs marathons, teaches biomedical entrepreneurship and volunteers with a disabled children NPO.

  • Dr. Efrat Kochba - Medical Director
    Dr. Efrat Kochba - Medical Director

    Dr. Efrat Kochba has joined NanoPass Technologies Ltd. in 2012 as medical director and is in charge of managing the clinical activities of the company, as well as business development and marketing activities.  Dr. Kochba brings a wide experience in the field of drug delivery working for TransPharma Medical Ltd., a company that focused on transdermal drug delivery. Efrat holds an MD degree from the Hebrew university in Jerusalem and practiced ENT medicine for six years prior to joining Roche pharmaceuticals as a medical and clinical trials manager.

  • Gal Admati - COO
    Gal Admati - COO

    Gal Admati joined NanoPass Technologies Ltd. In 2012. Gal is NanoPass' COO and oversees daily activities including marketing and sales, production, operations, R&D, quality, regulation and administration. Gal joined NanoPass as R&D director and was in charge of the company’s research and development activities as well as the company’s engineering activities and device manufacturing processes. Gal has experience in management, medical device research and development, machining, design, micro mechanics and mechanical automation. Gal has a B.Sc. in biomedical engineering and an MBA with a specialization in Strategy from Tel Aviv University

  • Ruth Safdia - Regulatory Affairs Director
    Ruth Safdia - Regulatory Affairs Director

    Ruth Safdia - Director of regulatory Affairs (female): Mrs Ruth Safdia (M.Sc. Medical Sciences - University of Tel- Aviv) joined NanoPass Technologies Ltd. on July 2019 as Director of Regulatory Affairs and responsible all the Company’s regulatory activities worldwide. Ruth Safdia has 15 years of experience in medical device regulatory affairs, industrial research, attaining European (CE) and USA (FDA) regulatory approvals/ clearance, biological safety evaluation, technical files submission, 510k and PMA submissions etc. as well as the strategic planning for regulatory approvals.


  • Tamir Shefer - Quality Assurance Director
    Tamir Shefer - Quality Assurance Director

    Tamir Shefer joined NanoPass Technologies Ltd. In March 2017 as QA director and is in charge of the quality processes of the organization.

    Tamir brings more than 20 years of experience in quality assurance and regulatory affairs compiling regulatory files to regulatory authorities and establishing and maintaining quality systems mainly in medical devices industry,

    for active and non-active devices including critical care devices, diagnostic devices, and active implants.

    Tamir worked for Philips Healthcare, Cheetah Medical, BioControl Medical, Direx, Given Imaging (acquired by Medtronic) and Biometrix Medical and holds a B.Sc. in biology from Technion Israel Institute of technology

  • Yoav Hamisha - Director of Operations and Product Development
    Yoav Hamisha  - Director of Operations and Product Development

    Yoav Hamisha joined NanoPass Technologies Ltd. In July 2018 as Director of Engineering and Product Development and is in charge of all company’s engineering and product development activities. Yoav has over 15 years of experience in mechanical engineering, Engineering management, mainly of Semiconductors industry, printing industry & medical devices industry, in the fields of non-invasive fat reduction. Yoav has a B.Sc. in Mechanical engineering from Ben Gurion University and worked for Nur Macroprinters Ltd, HP Scitex Ltd., Ultrashape Ltd. and Nova measuring instruments Ltd.

  • Quintin J. Lai - Director

    Quintin J. Lai, Ph.D., CFA serves as Vice President, Corporate Development, Strategy and Investor Relations. As a member of the senior leadership team at West, Dr. Lai oversees corporate strategy and investor relations. Prior to joining West, Dr. Lai served as Vice President of Investor Relations and Corporate Strategy at Sigma-Aldrich Corporation, where he was responsible for developing a global strategy for that S&P 500 company as well as creating an industry-leading IR function. From 2002-2012, Dr. Lai served as Managing Director and Senior Equity Research analyst of the Life Science Tools and Diagnostic sector at Robert W. Baird & Company. He also spent eight years as a Senior Research Engineer at Atlantic Richfield (ARCO). Dr. Lai holds a Bachelor of Science degree in Chemical Engineering from the University of Alabama, a doctoral degree in Chemical Engineering from the University of Wisconsin-Madison and a Masters of Business Administration degree from the University of Chicago Booth School of Business.

  • Marvin Samson - Director

    Mr. Samson, founder and CEO of Samson Medical Technologies and Chairman of the Board of Trustees of the University of the Sciences, was formerly a Group Vice President – Worldwide Injectables of Teva, previously having served as CEO and a member of the Board of Directors of Sicor (acquired in 2004 by Teva for $3.4 billion). He was also the CEO of Qualitest Pharmaceuticals. He is an expert in injectable manufacturing and delivery systems and was a founder and CEO of Elkins-Sinn (today, West-Ward Pharmaceuticals, one of the largest generic injectables companies in the U.S.) and Marsam Pharmaceuticals.

  • Dr. Hadar Ron - Director

    Dr. Ron is a physician and attorney. She has extensive medical, legal and management experience in insurance companies, law firms, medical and educational institutions. Her legal and management expertise includes venture capital consulting, medical malpractice, general and medical insurance and legal practice. Hadar holds an MD from the Sackler School of Medicine, Tel Aviv University, and an LL.B. in Law from Tel Aviv University.

  • Igal Kohn (Guli) - Director

    CEO of Elcam Medical ACS Ltd., a leading worldwide OEM supplier, servicing the medical industry in the area of Fluid Management, Vital Signs Monitoring and Drug Delivery, and the chairman of Elcam Medical US. Igal was Elcam Medical C.F.O since 1998 and holding Israeli CPA.  

  • Eylon Penchas - Director

    Eylon Penchas acts as Managing General Partner of Viola Partners (part of the Viola Group) from 2000. Eylon serves as a board member in several of the Viola Partners portfolio companies. He is also the Active Chairman of the Natie Kirsh Seed Fund – a philanthropic fund helping entrepreneurs start their new businesses with free interest loans. Prior to joining Viola Eylon acted as an investment banker at DS from 1997. Prior to joining DS Eylon served as Director of Business Development at Bezeq Telecommunications and as a Research Analyst at the Central Bank of Israel. Eylon holds a B.A. in Economics and an MBA in Finance from the Hebrew University in Jerusalem.

  • Assif Stoffman - Director

    Since January 2020, Mr. Stoffman is co-managing XT Hi-Tech, the venture capital arm of the global shipping & industrial group XT Holdings. Between 2012 and June 2018, Mr. Stoffman was the co-founder and CEO of MValve Technologies Ltd, pioneering a revolutionary concept in treating mitral valve disease. Prior to MValve, between 2009 and 2012 Mr. Stoffman served as Executive Vice President of XT Hi-Tech, in charge of software and healthcare investments. Mr. Stoffman was the founding investor and executive chairman of Checkmarx (acquired by Insight Venture Partners), and served on the board of directors of JetPrep (acquired by Cantel Medical; NYSE: CMD), CmyCasa (acquired by Adobe; NASDAQ: ADBE) and Activiews (acquired by Stryker; NYSE:SYK). Between 2004 and 2008 Mr. Stoffman was the CEO of Naiot Venture Accelerator, a leading healthcare and software accelerator, where he was leading the foundation of numerous start-up companies. Mr. Stoffman holds an LL.M. (negotiations and dispute resolution) degree from Bar-Ilan University and LL.B. and BA (Business Administration) degrees from the Interdisciplinary Center, Herzeliya.

  • Dr. Shuki Yeshurun - Founder

    Dr. Yeshurun brings two decades of MEMS and advanced materials R&D expertise to NanoPass. His work integrates both commercial and academic experience. Dr. Yeshurun has an established history in bringing multi-million dollar technology-intensive projects from a concept to the market. Dr. Yeshurun earned his B.Sc. in Mechanical engineering at the Beer Sheva University, and his M.Sc. and PhD in Advanced Materials at the Technion Institute of Technology. A prolific scholar, Dr. Yeshurun has authored over 40 professional publications and 50 classified reports. He is a lecturer at the Technion Institute. A Senior Scientist at NATIONAL LAB, Dr. Yeshurun was a group leader in charge of developing piezoelectric materials for MEMS applications. Dr. Yeshurun holds over a dozen patents and was awarded the American Ceramic Society “Rose” Award for his work. He serves as member of the Board of Directors.

Our vision

NanoPass’s vision is to improve health and wellbeing of people worldwide. We do this by harnessing clinical innovation for developing new benefits for existing products, new applications and new combinations, while redefining product delivery in aesthetics and immunology. We provide consistent, easy to use, shallow and painless intradermal delivery solutions.

Strategic Relationships

NanoPass has strategic relationships with:

  • West Pharmaceutical Services
  • Infectious Diseases Research Institute, Seattle: Global health vaccines (Tuberculosis, pandemic flu)
  • Additional partners in the EU, China, South Korea and others.

Quality Policy

  • NanoPass takes responsibility for the complete satisfaction of its customers
  • NanoPass focuses on developing and manufacturing devices that improve the wellbeing of all patients using them
  • NanoPass is committed to complying with the requirements and maintaining the effectiveness of the Quality Management System
    The principles defined in this Quality Policy will be translated into specific goals and objectives for all levels of the organization
  • We exercise this responsibility through adequate training of our employees, adherence to proven procedures, complying with international and local laws and regulations, and maintaining a company culture that encourages excellence
  • Our main objective is to assure that our customers will receive quality products that meet these requirements on time, every time